FDA: Certain COVID-19 tests must evaluate how variants affect performance
The Food and Drug Administration today certain COVID-19 test developers to evaluate how SARS-CoV-2 mutations impact their test鈥檚 performance and update the labeling for the product accordingly. The new conditions for emergency use authorization pertain to certain authorized molecular, antigen and .
Related News Articles
Headline
The Food and Drug Administration today issued an alert on a potentially high-risk issue with Calyxo CVAC Aspiration Systems. In patients who have thick fluid鈥
Headline
In this conversation, Carlos Roberts, M.D., urogynecologist, vice president and chief medical officer of the Women and Children service line at WellSpan Health鈥
Headline
In this 鈥淪afety Speaks鈥 conversation, CommonSpirit Health's Beth Miller, system director, patient safety-performance improvement, and Austin Peterson, system鈥
Headline
CDC recommends two doses of COVID-19 vaccine for older individuals, lowers pneumococcal vaccine age聽
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to鈥
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition鈥
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-鈥